reason report
recap steadi progress maintain expect
bottom line achn expect report five interim data readout
decemb quarter compani complet
enrol monotherapi trial evalu lead asset
paroxysm nocturn hemoglobinuria pnh
addit trial evalu drug add-on
alexion op soliri anticip readout
compani also report data dec two on-going studi
evalu proof-mechanism/concept complement factor
cfd inhibitor platform glomerulopathi lastli investor
also expect data achn emerg pipelin cfd inhibitor
dec updat model reflect financi achn end
quarter cash equival reiter op achn
achn provid investor comprehens portfolio
strateg updat decemb follow complet enrol
pnh monotherapi trial last quarter achn report data
cfd inhibitor platform pnh mono- add-on
therapi pertain think interim efficaci data
open-label proof-of-concept studi could needle-
move stock provid first insight
long-term efficaci rare kidney diseas approv
treatment wherebi achn could emerg leader among hand
competitor vy first-to-market statu taken togeth data
long await strateg updat set accompani
releas provid clearer pictur recent appoint
ceo joseph truitt execut compani clinic pipelin
pipelin compani conduct studi evalu
safeti pharmacokinet second gener oral cfd
inhibitor although manag
yet disclos indic compound use
investor soon know second gener show promis
improv half-lif potenc result single-
ascend dose studi also report year
chang model updat model reflect
compani report financi result addit updat
estim opex accord compani guid project
dcf discount rate
compani inform leerink partner llc research
ep
pleas refer page import disclosur price chart analyst certif
achn biopharmaceut compani portfolio direct
antivir agent daa complement factor cfd inhibitor clinic develop lead
candid investig complement-medi diseas paroxysm
nocturn hemoglobinuria pnh glomerulopathi complex mediat
rel less well understood achn employ systemat approach design
cfd inhibitor program believ share could appreci meaning
manag demonstr favor efficaci safeti lead cfd candid beyond
achn could leverag proprietari portfolio cfd inhibitor
increas expertis complement biolog target broad array diseas irrespect
rout administr near-term catalyst includ addit data pnh
larger market opportun may includ geograph atrophi ga longer term remain
intrigu cfd platform view next month import time valid
pt base discount cash flow dcf analysi incorpor variou
complement-medi diseas pnh current estim penetr
estim pnh/ahu patient whose diseas well control
alxn soliri roughli treatment-nav pnh patient assum peak penetr
coincid expir orphan drug exclus ode us order account
potenti gener competit also includ potenti revenu glomerulopathi
geograph atrophi ga assign probabl respect reflect
earli stage develop achn complement inhibitor portfolio benefit
extens patent protect last whose extens could strengthen
longev revenu stream pre-commerci compani appli discount
rate termin growth rate consist similarli situat compani
coverag bold
risk valuat includ competit risk product receiv approv enter
commerci risk associ clinic trial regulatori review
research develop
chang cash
discount rate/cost equiti
interim data phase ii pnh studi partial respond eculizumab
data read phase ii poc trial mo dose
